Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Future challenges for rivaroxaban uptake in patients with AF include unfamiliarity with management of interruption and bleeding, and cost of the drug. The site of action of rivaroxaban and vitamin ...

The pharmacological advantages of rivaroxaban and the favorable results of the ROCKET AF trial suggest that it will be preferred to warfarin in the majority of patients with AF who have additional ...